Overview An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis Status: Completed Trial end date: 2018-03-01 Target enrollment: Participant gender: Summary Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis Phase: Phase 2 Details Lead Sponsor: Galectin Therapeutics Inc.